Julie A Andersen

US Patent:

20090111748, Apr 30, 2009

Filed:

Jul 21, 2006

Appl. No.:

11/996178

Inventors:

Lisa M. Ellerby - Novato CA, US
David A. Greenberg - Sonoma CA, US
Julie Andersen - Novato CA, US
Kunlin Jin - Novato CA, US

International Classification:

A61K 38/18

US Classification:

514 12

Abstract:

This invention pertains to the discovery that fibroblast growth factor 2 (FGF2) stimulates neurogenesis, induces migration of newborn cells into the striatum and cortex, is neuroprotective, and significantly extends the lifespan mammals suffering from neurodegenerative conditions (e.g., Huntington's disease, Parkinson's disease, etc.). In certain embodiments this invention provides a method of promoting neurogenesis, neuroprotection and/or survival in a mammal having a neurodegenerative disease by upregulating expression or availability of endogenous fibroblast growth factor 2 (FGF2) in said mammal; and/or administering FGF2 or an FGF2 mutein to the mammal in an amount sufficient to promote neurogenesis, neuroprotection and/or survival of the mammal.

US Patent:

20110067123, Mar 17, 2011

Filed:

Feb 18, 2009

Appl. No.:

12/867233

Inventors:

Julie Andersen - Novato CA, US
Jyothi Kumar Mallajosyula - Carlsbad CA, US

International Classification:

A01K 67/027
C12Q 1/68
C40B 30/04
G01N 33/573
C12Q 1/26
A61K 31/137
A61K 31/135
A61K 31/44
A61K 31/4245
A61K 31/536
A61K 31/16
A61P 25/16

US Classification:

800 9, 435 6, 506 9, 435 74, 435 25, 514654, 514655, 514657, 514354, 514364, 5142305, 514626

Abstract:

This invention pertains to development of a new animal model for Parkinson's Disease (PD) and to the discovery that elevated monoamine oxygenase B (MOA-B) expression and/or activity is a strong prognostic indicator for the disease. Accordingly, in certain embodiments, methods are provided for identifying a mammal at risk for Parkinson's disease. The methods typically involve determining level of expression or activity of monoamine oxidase B (MAO-B) in a sample from the mammal wherein an elevated level of MAO-B expression and/or activity as compared to a control (reference) is an indicator that the mammal has an increased likelihood of developing Parkinson's disease.

US Patent:

20130017274, Jan 17, 2013

Filed:

Mar 16, 2012

Appl. No.:

13/422960

Inventors:

JULIE K. ANDERSEN - Novato CA, US
HWAN KIM - San Francisco CA, US

Assignee:

BUCK INSTITUTE FOR RESEARCH ON AGING - Novato CA

International Classification:

A61K 33/14
A61P 25/16

US Classification:

424677

Abstract:

In various embodiments methods of delaying the onset of and/or mitigating the severity of one or more symptoms of Parkinson's disease in a mammal are provided. In certain embodiments the methods involve administering to a mammal diagnosed as having or as at risk for Parkinson's disease a chronic low dose of lithium (e.g., a subtherapeutic dose). In certain embodiments the low dose lithium is administered in conjunction with another agent (e.g., L-DOPA).

US Patent:

20040101521, May 27, 2004

Filed:

Jul 11, 2003

Appl. No.:

10/618444

Inventors:

Julie Andersen - Novato CA, US

Assignee:

The Buck Institute for Research on Aging

International Classification:

A61K048/00
A61K031/47
A61K031/195
A61K038/40

US Classification:

424/093210, 514/006000, 514/311000, 514/566000

Abstract:

This invention pertains to the discovery that elevated level of free iron causal in the onset and/or progression of diseases characterized by neural degeneration (e.g., Parkinson's Disease). It was also discovered that lowering free iron levels can inhibit (e.g. reduce or eliminate) the onset and/or progression of one or more symptoms of such diseases. Thus, in one embodiment this invention provides a method of inhibiting neural degeneration in a mammal. The method involves reducing free iron levels in a neural tissue of said animal in an amount sufficient to inhibit neural degeneration in said neural tissue.

US Patent:

20220265605, Aug 25, 2022

Filed:

Feb 5, 2020

Appl. No.:

17/428600

Inventors:

- Novato CA, US
Julie K. Andersen - Novato CA, US
Shankar J. Chinta - Novato CA, US
Manish Chamoli - San Mateo CA, US

Assignee:

Buck Institute for Research on Aging - Novato CA

International Classification:

A61K 31/37
A61K 31/4745
A61P 25/28
A61K 31/5377

Abstract:

In various embodiments compounds that induce and/or promote autophagy are provided as wells as methods of use thereof (e.g., in the prophylaxis or treatment of chronic pathologies associated with aging). In one illustrative, but non-limiting embodiments the compound(s) comprise, inter alia, coumarin 106.